Biogen INC 8-K filings

Biogen Inc. announced robust second quarter 2026 financial results, with total revenue reaching $2.7 billion, a 3% year-over-year increase, driven by significant growth in its 'Growth Portfolio'.

Biogen Inc. anticipates significant acquired R&D expenses in Q2 and Q3 2026, impacting EPS.

Biogen Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of ten directors and the ratification of its independent auditor.

Biogen Inc. amends its prior Form 8-K filing regarding the acquisition of Apellis Pharmaceuticals, Inc., stating that financial statements are not required as the acquisition was not significant.

Biogen Inc. has successfully acquired Apellis Pharmaceuticals, Inc., adding two key commercial products and strengthening its position in nephrology and complement-driven diseases.

Biogen announced robust first quarter 2026 financial results, with total revenue reaching $2.5 billion and GAAP diluted EPS surging 31% year-over-year, driven by strong performance in its growth products and pipeline advancements.

Biogen expects a $34 million pre-tax charge for acquired in-process research and development in the first quarter of 2026.

Biogen announced a definitive agreement to acquire Apellis Pharmaceuticals for $5.6 billion upfront cash plus contingent value rights, expanding its immunology and rare disease portfolio.

Biogen Inc. announced that Caroline Dorsa will not seek re-election as Board Chair, with Dr. Maria C. Friere elected to succeed her.

Biogen reported strong fourth quarter and full year 2025 financial results, surpassing its full-year Non-GAAP diluted EPS guidance, while projecting a mid-single digit revenue decline for 2026.

Biogen Inc. anticipates a pre-tax charge of approximately $222 million for acquired in-process research and development, upfront, and milestone expenses in its fourth quarter 2025 results, impacting EPS by $1.26.

Biogen Inc. announced robust third-quarter 2025 financial results, driven by strong launch product growth and an updated full-year revenue guidance, despite a revised EPS outlook due to business development investments.

Biogen Inc. anticipates a pre-tax acquired in-process research and development expense of approximately $2 million for Q3 2025, impacting diluted EPS by $0.01.

Biogen Inc. announced robust second quarter 2025 financial results, driven by strong growth in new product launches and pipeline advancements, leading to an increase in its full-year 2025 financial guidance.

Biogen Inc. anticipates a pre-tax charge of approximately $46 million for acquired in-process research and development, upfront, and milestone expenses in the second quarter of 2025, expected to reduce diluted earnings per share by $0.26.

Biogen Inc. announced the final voting results from its 2025 Annual Meeting of Stockholders, confirming the election of eleven directors, the ratification of PricewaterhouseCoopers LLP as its independent auditor, and the approval of executive compensation.

Biogen Inc. has successfully issued $1.75 billion in senior notes to refinance its 2025 senior notes and for general corporate purposes.

Biogen's first quarter 2025 results show a 6% year-over-year revenue increase, driven by growth in rare disease and launch products, despite a decline in multiple sclerosis revenue.

Biogen announces its fourth quarter and full year 2024 financial results, highlighting revenue growth in key areas and providing financial guidance for 2025.

Biogen has appointed Sean Godbout as its new Chief Accounting Officer, effective March 1, 2025, while Robin Kramer will transition to Chief Financial Officer upon Michael McDonnell's retirement.

Biogen's Chief Financial Officer, Michael McDonnell, will retire in February 2025, with Robin Kramer, currently Chief Accounting Officer, appointed as his successor.

Biogen's third quarter results show revenue of $2.5 billion, with product launches driving growth and an increase in full year 2024 financial guidance.

Biogen has expanded its Board of Directors with the appointment of Dr. Lloyd Minor and Prof Sir Menelas Pangalos, effective October 1, 2024 and January 1, 2025, respectively.

Biogen Inc. has entered into a new $1.5 billion revolving credit agreement, replacing its previous credit facility.

Biogen's second quarter of 2024 saw flat revenue growth but a significant increase in non-GAAP EPS, leading to an improved full-year financial outlook.

Biogen's stockholders approved an amendment to the company's charter to allow for officer exculpation and elected nine directors at the 2024 Annual Meeting.

Biogen's first quarter of 2024 saw a 1% increase in GAAP EPS and an 8% increase in non-GAAP EPS, despite a 7% decrease in total revenue.

Biogen's 2023 results show a mixed performance with revenue declines but the company anticipates a return to non-GAAP EPS growth in 2024.